Abstract
Statin interference has been suggested among the mechanisms of reduction of the antiplatelet effect of clopidogrel. We thus sought to assess the influence of rosuvastatin on clopidogrel antiplatelet action in high-risk (HR) cardiovascular patients. To set the level of platelet inhibition by combined antithrombotic treatments we retrospectively studied two populations of HR patients, one under aspirin alone, the other under aspirin plus rosuvastatin, before and after addition of clopidogrel. The effects of rosuvastatin compared with atorvastatin were then prospectively investigated in patients who underwent percutaneous coronary intervention (PCI), under clopidogrel and aspirin treatment. Light transmission platelet aggregation (LTA) was studied in response to adenosine diphosphate (ADP) (5 μM) or arachidonic acid (0.5 mM). The inhibitory effect of clopidogrel in reducing ADP-induced LTA was similar in the two HR groups of patients. No difference in ADP-induced platelet aggregation was observed in the two PCI groups of patients with either atorvastatin or rosuvastatin. In conclusion, rosuvastatin does not interfere with the antiplatelet effect of clopidogrel in patients with cardiovascular disease.
| Original language | English |
|---|---|
| Pages (from-to) | 151-155 |
| Number of pages | 5 |
| Journal | Journal of Thrombosis and Thrombolysis |
| Volume | 28 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2009 |
Fingerprint
Keywords
- Aspirin
- Clopidogrel
- Platelet aggregation
- Rosuvastatin
ASJC Scopus subject areas
- Hematology
- Cardiology and Cardiovascular Medicine
Cite this
Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. / Riondino, Silvia; Petrini, Natalia; Donato, Luciamaria; Torromeo, Concetta; Tanzilli, Gaetano; Pulcinelli, Fabio M.; Barillà, Francesco.
In: Journal of Thrombosis and Thrombolysis, Vol. 28, No. 2, 2009, p. 151-155.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients
AU - Riondino, Silvia
AU - Petrini, Natalia
AU - Donato, Luciamaria
AU - Torromeo, Concetta
AU - Tanzilli, Gaetano
AU - Pulcinelli, Fabio M.
AU - Barillà, Francesco
PY - 2009
Y1 - 2009
N2 - Statin interference has been suggested among the mechanisms of reduction of the antiplatelet effect of clopidogrel. We thus sought to assess the influence of rosuvastatin on clopidogrel antiplatelet action in high-risk (HR) cardiovascular patients. To set the level of platelet inhibition by combined antithrombotic treatments we retrospectively studied two populations of HR patients, one under aspirin alone, the other under aspirin plus rosuvastatin, before and after addition of clopidogrel. The effects of rosuvastatin compared with atorvastatin were then prospectively investigated in patients who underwent percutaneous coronary intervention (PCI), under clopidogrel and aspirin treatment. Light transmission platelet aggregation (LTA) was studied in response to adenosine diphosphate (ADP) (5 μM) or arachidonic acid (0.5 mM). The inhibitory effect of clopidogrel in reducing ADP-induced LTA was similar in the two HR groups of patients. No difference in ADP-induced platelet aggregation was observed in the two PCI groups of patients with either atorvastatin or rosuvastatin. In conclusion, rosuvastatin does not interfere with the antiplatelet effect of clopidogrel in patients with cardiovascular disease.
AB - Statin interference has been suggested among the mechanisms of reduction of the antiplatelet effect of clopidogrel. We thus sought to assess the influence of rosuvastatin on clopidogrel antiplatelet action in high-risk (HR) cardiovascular patients. To set the level of platelet inhibition by combined antithrombotic treatments we retrospectively studied two populations of HR patients, one under aspirin alone, the other under aspirin plus rosuvastatin, before and after addition of clopidogrel. The effects of rosuvastatin compared with atorvastatin were then prospectively investigated in patients who underwent percutaneous coronary intervention (PCI), under clopidogrel and aspirin treatment. Light transmission platelet aggregation (LTA) was studied in response to adenosine diphosphate (ADP) (5 μM) or arachidonic acid (0.5 mM). The inhibitory effect of clopidogrel in reducing ADP-induced LTA was similar in the two HR groups of patients. No difference in ADP-induced platelet aggregation was observed in the two PCI groups of patients with either atorvastatin or rosuvastatin. In conclusion, rosuvastatin does not interfere with the antiplatelet effect of clopidogrel in patients with cardiovascular disease.
KW - Aspirin
KW - Clopidogrel
KW - Platelet aggregation
KW - Rosuvastatin
UR - http://www.scopus.com/inward/record.url?scp=67849083185&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67849083185&partnerID=8YFLogxK
U2 - 10.1007/s11239-008-0254-6
DO - 10.1007/s11239-008-0254-6
M3 - Article
C2 - 18636229
AN - SCOPUS:67849083185
VL - 28
SP - 151
EP - 155
JO - Journal of Thrombosis and Thrombolysis
JF - Journal of Thrombosis and Thrombolysis
SN - 0929-5305
IS - 2
ER -